Identification

Name
Cefpodoxime
Accession Number
DB01416
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.

Structure
Thumb
Synonyms
  • Cefpodoxima
  • Cefpodoximum
External IDs
RU 51807
Product Ingredients
IngredientUNIICASInChI Key
Cefpodoxime proxetil2TB00A1Z7N87239-81-4LTINZAODLRIQIX-FBXRGJNPSA-N
Cefpodoxime sodium3ULP5169B382619-04-3JNMXSNGAMPXCDR-XYNKDNFRSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OreloxTablet100 mgOralSanofi AventisNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cefpodoxime ProxetilGranule, for suspension50 mg/5mLOralRising Pharmaceuticals2007-06-08Not applicableUs
Cefpodoxime ProxetilTablet, film coated100 mg/1OralCronus Pharma LLC2007-06-11Not applicableUs
Cefpodoxime ProxetilGranule, for suspension50 mg/5mLOralNorth Star Rx Llc2007-06-08Not applicableUs
Cefpodoxime ProxetilTablet, film coated100 mg/1OralPutney, Inc.2008-05-28Not applicableUs
Cefpodoxime ProxetilTablet, film coated200 mg/1OralAurobindo Pharma2007-06-11Not applicableUs
Cefpodoxime ProxetilGranule, for suspension100 mg/5mLOralSandoz2009-06-25Not applicableUs
Cefpodoxime ProxetilTablet, film coated100 mg/1OralGen Source Rx2007-06-11Not applicableUs
Cefpodoxime ProxetilTablet, film coated100 mg/1OralSandoz2008-05-28Not applicableUs
Cefpodoxime ProxetilTablet, film coated100 mg/1OralOrchid Pharma Inc2016-09-15Not applicableUs
Cefpodoxime ProxetilTablet, film coated200 mg/1OralNorth Star Rx Llc2007-06-11Not applicableUs
International/Other Brands
Banan / Doxef
Categories
UNII
7R4F94TVGY
CAS number
80210-62-4
Weight
Average: 427.455
Monoisotopic: 427.062024681
Chemical Formula
C15H17N5O6S2
InChI Key
WYUSVOMTXWRGEK-HBWVYFAYSA-N
InChI
InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
IUPAC Name
(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][[email protected]]12SCC(COC)=C(N1C(=O)[[email protected]]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O

Pharmacology

Indication

For the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms.

Structured Indications
Pharmacodynamics

Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis.

Mechanism of action

Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicillin binding protein 3, which inhibits production of peptidoglycan, the primary constituent of bacterial cell walls.

TargetActionsOrganism
APeptidoglycan synthase FtsI
inhibitor
Escherichia coli (strain K12)
Absorption

Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the administered cefpodoxime dose was absorbed systemically.

Volume of distribution
Not Available
Protein binding

22 to 33% in serum and from 21 to 29% in plasma.

Metabolism
Not Available
Route of elimination

Over the recommended dosing range (100 to 400 mg), approximately 29 to 33% of the administered cefpodoxime dose was excreted unchanged in the urine in 12 hours.

Half life

2.09 to 2.84 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcenocoumarolCefpodoxime may increase the anticoagulant activities of Acenocoumarol.Approved
AlmasilateThe serum concentration of Cefpodoxime can be decreased when it is combined with Almasilate.Approved, Experimental
AloglutamolThe serum concentration of Cefpodoxime can be decreased when it is combined with Aloglutamol.Experimental
AluminiumThe serum concentration of Cefpodoxime can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Cefpodoxime can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Cefpodoxime can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Cefpodoxime can be decreased when it is combined with Aluminum hydroxide.Approved
AsenapineAsenapine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cefpodoxime.Investigational
Bismuth SubcitrateThe serum concentration of Cefpodoxime can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Cefpodoxime can be decreased when it is combined with Bismuth subnitrate.Experimental
Calcium CarbonateThe serum concentration of Cefpodoxime can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Cefpodoxime can be decreased when it is combined with Calcium silicate.Experimental
CimetidineCimetidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClorindioneCefpodoxime may increase the anticoagulant activities of Clorindione.Experimental
DicoumarolCefpodoxime may increase the anticoagulant activities of Dicoumarol.Approved
DiphenadioneCefpodoxime may increase the anticoagulant activities of Diphenadione.Experimental
DoxepinDoxepin can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EpinastineEpinastine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ethyl biscoumacetateCefpodoxime may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FamotidineFamotidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluindioneCefpodoxime may increase the anticoagulant activities of Fluindione.Investigational
HydrotalciteThe serum concentration of Cefpodoxime can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
MagaldrateThe serum concentration of Cefpodoxime can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium Trisilicate.Approved
MethanthelineMethantheline can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MetiamideMetiamide can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
NizatidineNizatidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OlanzapineOlanzapine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PhenindioneCefpodoxime may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonCefpodoxime may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefpodoxime.Approved
ProbenecidThe serum concentration of Cefpodoxime can be increased when it is combined with Probenecid.Approved
PromethazinePromethazine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RanitidineRanitidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Roxatidine acetateRoxatidine acetate can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Sodium bicarbonateThe serum concentration of Cefpodoxime can be decreased when it is combined with Sodium bicarbonate.Approved
TioclomarolCefpodoxime may increase the anticoagulant activities of Tioclomarol.Experimental
TromethamineThe serum concentration of Cefpodoxime can be decreased when it is combined with Tromethamine.Approved
WarfarinCefpodoxime may increase the anticoagulant activities of Warfarin.Approved
Food Interactions
  • Take on empty stomach: 1 hour before or 2 hours after meals.

References

Synthesis Reference

Yatendra Kumar, Neera Tewari, Ram Aryan, Bishwa Rai, Hashim Nizar, "Process for the preparation of cefpodoxime acid." U.S. Patent US20050020561, issued January 27, 2005.

US20050020561
General References
Not Available
External Links
Human Metabolome Database
HMDB15486
KEGG Compound
C08114
PubChem Compound
6335986
PubChem Substance
46504897
ChemSpider
4891496
BindingDB
50292251
ChEBI
3504
ChEMBL
CHEMBL1672
Therapeutic Targets Database
DAP000457
PharmGKB
PA164746385
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cefpodoxime
ATC Codes
J01DD13 — Cefpodoxime
AHFS Codes
  • 08:12.06.12 — Third Generation Cephalosporins
FDA label
Download (369 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedTreatmentDiarrhea / Neoplasms1
1CompletedTreatmentNeuroblastomas1
1CompletedTreatmentTumors, Solid1
Not AvailableActive Not RecruitingOtherAnti-Bacterial Agents / Microbiota1
Not AvailableCompletedTreatmentUrinary Tract Infections (UTIs)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Granule, for suspensionOral100 mg/5mL
Granule, for suspensionOral50 mg/5mL
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral200 mg/1
TabletOral100 mg
Prices
Unit descriptionCostUnit
Vantin 20 200 mg tablet Bottle194.37USD bottle
Vantin 20 100 mg tablet Bottle137.26USD bottle
Vantin 100 mg/5ml Suspension 100ml Bottle133.84USD bottle
Vantin 50 mg/5ml Suspension 100ml Bottle70.34USD bottle
Vantin 50 mg/5ml Suspension 50ml Bottle36.95USD bottle
Vantin 200 mg tablet9.67USD tablet
Cefpodoxime Proxetil 200 mg tablet7.02USD tablet
Cefpodoxime 200 mg tablet6.41USD tablet
Vantin 100 mg tablet6.33USD tablet
Cefpodoxime 100 mg tablet5.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.185 mg/mLALOGPS
logP0.05ALOGPS
logP-1.2ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)3.22ChemAxon
pKa (Strongest Basic)4.16ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area156.44 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity100.71 m3·mol-1ChemAxon
Polarizability39.9 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5556
Blood Brain Barrier-0.984
Caco-2 permeable-0.7549
P-glycoprotein substrateSubstrate0.7587
P-glycoprotein inhibitor INon-inhibitor0.8753
P-glycoprotein inhibitor IIInhibitor0.6389
Renal organic cation transporterNon-inhibitor0.8645
CYP450 2C9 substrateNon-substrate0.8729
CYP450 2D6 substrateNon-substrate0.8183
CYP450 3A4 substrateSubstrate0.535
CYP450 1A2 substrateNon-inhibitor0.7905
CYP450 2C9 inhibitorNon-inhibitor0.8017
CYP450 2D6 inhibitorNon-inhibitor0.8895
CYP450 2C19 inhibitorNon-inhibitor0.7558
CYP450 3A4 inhibitorNon-inhibitor0.7875
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9144
Ames testNon AMES toxic0.8249
CarcinogenicityNon-carcinogens0.8656
BiodegradationNot ready biodegradable0.9863
Rat acute toxicity1.9732 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9764
hERG inhibition (predictor II)Non-inhibitor0.8162
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephalosporins
Alternative Parents
N-acyl-alpha amino acids and derivatives / 2,4-disubstituted thiazoles / 1,3-thiazines / 2-amino-1,3-thiazoles / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Amino acids / Azetidines / Dialkylthioethers
show 10 more
Substituents
Cephalosporin / N-acyl-alpha amino acid or derivatives / Alpha-amino acid or derivatives / 2,4-disubstituted 1,3-thiazole / Meta-thiazine / 1,3-thiazol-2-amine / Heteroaromatic compound / Azole / Thiazole / Tertiary carboxylic acid amide
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cephalosporin, carboxylic acid (CHEBI:3504)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Peptidoglycan glycosyltransferase activity
Specific Function
Essential cell division protein that is required for the synthesis of peptidoglycan at the division septum (PubMed:1103132, PubMed:9614966). Catalyzes the synthesis of cross-linked peptidoglycan fr...
Gene Name
ftsI
Uniprot ID
P0AD68
Uniprot Name
Peptidoglycan synthase FtsI
Molecular Weight
63876.925 Da
References
  1. Boaretti M, Lleo MM, Canepari P: In vitro activity, beta-lactamase stability and PBP affinity of RU 51,746-2, the active metabolite of the new orally absorbed cephalosporin ester, RU 51807. J Chemother. 1991 Jan;3 Suppl 1:57-61. [PubMed:12041787]

Drug created on July 23, 2007 07:09 / Updated on January 14, 2018 10:04